To better serve those clinicians and researchers working on autoimmune liver diseases, the Special Interest Group (SIG) formerly known as the Cholestatic and Biliary Diseases SIG has undergone a name change and expanded mission.
The “new” SIG is called the Cholestatic and Autoimmune Liver Diseases SIG.
“The previous focus of the group was on cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), both of which are immune mediated, said SIG Chair Christopher L. Bowlus, MD, FAASLD. “The clinicians that typically take care of those patients often also care for those with autoimmune hepatitis, and in fact autoimmune hepatitis can occur in patients with either PBC or PSC.”
Dr. Bowlus noted that the physicians and researchers who focus on autoimmune hepatitis didn’t really have a home within AASLD’s SIG structure, but they now fit well into the mission of the renamed SIG.
“This will allow for more interaction between those members who may focus primarily on PSC or PBC, but have a secondary interest in autoimmune hepatitis with those who have a primary interest in autoimmune hepatitis, and vice versa” he said.
The SIG has hit the ground running with its expanded mission. It recently hosted an Emerging Trends Conference on cholangiopathies and currently is working on a webinar based on information from the conference. The SIG members are also busy planning this year’s SIG program which will focus on autoimmune hepatitis for The Liver Meeting® in November.
“We would ask for those members who have an interest in any of the autoimmune liver diseases, whether they be cholestatic or autoimmune hepatitis to join the SIG,” said Dr. Bowlus, who is Professor and Division Chief of Gastroenterology and Hepatology at UC Davis Health. “It’s a great opportunity for interactions, new collaborations and initiatives.”
To learn more about the Cholestatic and Autoimmune Liver Diseases SIG or to become a member, click here.